Cartesian Therapeutics Q1 net loss widens on higher R&D costs

Cartesian Therapeutics

30/04/2026 12:28

Overview

US cell therapy developer's Q1 revenue fell sharply, with minimal grant and no collaboration income

Net loss widened yr/yr, driven by higher R&D expenses for Phase 3 AURORA trial

Company ended Q1 with $120.4 mln cash, seen funding operations into mid-2027

Outlook

Company expects cash resources to support operations into mid-2027, including Phase 3 AURORA trial completion

Result Drivers

R&D SPENDING - Higher research and development expenses driven by ongoing Phase 3 AURORA trial for Descartes-08 in myasthenia gravis

PIPELINE ADVANCEMENT - Initiation of Phase 2 TRITON trial in myositis and enrollment in pediatric HELIOS trial increased development costs

LOWER ADMIN COSTS - General and administrative expenses decreased due to lower professional and consulting fees

Company press release: ID:nGNX4ww6tQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$39.18 mln
Q1 Operating Expenses
$26.58 mln
Q1 Operating Income
-$26.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $39.00, about 502.8% above its April 29 closing price of $6.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)